The Pharmacologic Treatment of Stuttering and Its Neuropharmacologic Basis
Stuttering is a DSM V psychiatric condition for which there are no FDA-approved medications for treatment. A growing body of evidence suggests that dopamine antagonist medications are effective in reducing the severity of stuttering symptoms. Stuttering shares many similarities to Tourette’s Syndrom...
Main Authors: | Gerald A. Maguire, Diem L. Nguyen, Kevin C. Simonson, Troy L. Kurz |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-03-01
|
Series: | Frontiers in Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fnins.2020.00158/full |
Similar Items
-
Investigation of Risperidone Treatment Associated With Enhanced Brain Activity in Patients Who Stutter
by: Gerald A. Maguire, et al.
Published: (2021-02-01) -
Report of a Rare Case of Olanzapine and Risperidone Induced Hypomania
by: AR Zahiroddin, et al.
Published: (2006-07-01) -
Stuttering : an integrated approach to its nature and treatment /
by: 394615 Guitar, Barry
Published: (2006) -
The neuropsychology of developmental stuttering /
by: 212123 Hartman, Bernard-thomas
Published: (1994) -
STUTTERING THERAPY FOR A CHILD AT INTERMEDIATE STUTTERING LEVEL
by: Nevzeta SALIHOVIKJ, et al.
Published: (2009-11-01)